Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PPP2CA-DT appears to reference a transcript variant from the *PPP2CA* gene, which encodes the catalytic alpha subunit of protein phosphatase 2A, a crucial enzyme in cell signaling, division, and apoptosis[1][2]. There is no robust published evidence describing PPP2CA-DT as a distinct molecular target, therapeutic entity, or receptor; scientific literature focuses on the canonical protein and its functional roles as an enzyme and tumor suppressor. Transcript variants of *PPP2CA* are not well-characterized as separate drug targets. The reference to "divergent transcript" may be misapplied, overly generic, or stemming from unclear data annotation. If you require information on the canonical *PPP2CA*-encoded enzyme rather than its divergent transcripts, please specify; full details and classifications are available for Protein Phosphatase 2A catalytic subunit alpha. Otherwise, current sources do not support PPP2CA-DT as a valid, actionable, or characterized drug target[1][2].
Null (no drugs known to target PPP2CA-DT)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein phosphatase 2 catalytic subunit alpha divergent transcript (PPP2CA-DT).